Evidence map›Paper›PMID 29481968›Full record

ArticleExperimental gerontology2018

High levels of an endothelial dysfunction marker (sVCAM-1) are associated with injurious and recurrent falls and mortality over a 5-year interval in an older population.

Achille Tchalla, Gregory A Wellenius, Sophie Boyer, Thomas G Travison, Daniel Habtemariam, Margaret Gagnon, Ikechukwu Iloputaife, Farzaneh A Sorond, Thierry Dantoine, Lewis A Lipsitz

Open access · greenAbstract read
In one paragraph

Article in Experimental gerontology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Achille TchallaInstitute for Aging Research, Hebrew SeniorLife, Boston, MA, USA; Beth Israel Deaconess Medical Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Limoges University, IFR 145 GEIST, EA 6310 HAVAE (Disability, Activity, Aging, Autonomy and Environment), Geriatric Medicine Department, CHU Limoges, Limoges F-87025, France.. Electronic address: Achille.tchalla@unilim.fr.
Gregory A WelleniusBrown University School of Public Health, Providence, MA, USA.
Sophie BoyerLimoges University, IFR 145 GEIST, EA 6310 HAVAE (Disability, Activity, Aging, Autonomy and Environment), Geriatric Medicine Department, CHU Limoges, Limoges F-87025, France.
Thomas G TravisonInstitute for Aging Research, Hebrew SeniorLife, Boston, MA, USA; Beth Israel Deaconess Medical Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Daniel HabtemariamInstitute for Aging Research, Hebrew SeniorLife, Boston, MA, USA.
Margaret GagnonInstitute for Aging Research, Hebrew SeniorLife, Boston, MA, USA.
Ikechukwu IloputaifeInstitute for Aging Research, Hebrew SeniorLife, Boston, MA, USA.
Farzaneh A SorondDepartment of Neurology, Stroke Division, Brigham and Women's Hospital, 45 Francis St, Boston, MA 02115, USA.
Thierry DantoineLimoges University, IFR 145 GEIST, EA 6310 HAVAE (Disability, Activity, Aging, Autonomy and Environment), Geriatric Medicine Department, CHU Limoges, Limoges F-87025, France.
Lewis A LipsitzInstitute for Aging Research, Hebrew SeniorLife, Boston, MA, USA; Beth Israel Deaconess Medical Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Hebrew SeniorLife · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USBrown University · USHarvard University · US

Funding

Translational Researchin Aging Trainnig ProgramT32AG023480 · NIA · HEBREW REHABILITATION CENTER FOR AGED · PI LIPSITZ, LEWIS · 2004 to 2024
$7.6M
Cerebral Small Vessels in Motor and Cognitive Decline: Neuroimaging Signatures of Vulnerability & ResilienceR01NS085002 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FARZANEH A SOROND · 2014 to 2026
$3.8M
Cerebrovascular Mechanisms of Slow Gait and FallsR01AG041785 · NIA · HEBREW REHABILITATION CENTER FOR AGED · PI LIPSITZ, LEWIS · 2013 to 2017
$2.4M
NIA NIH HHS R01 AG041785NIA NIH HHS T32 AG023480NINDS NIH HHS R01 NS085002
6 · The paper itself

Abstract

We investigated the association between elevated plasma concentrations of circulating soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and injurious falls and mortality over a 5-year period. We studied the prospective relationship between levels of circulating adhesion molecules and falls in 680 community-dwelling participants in the MOBILIZE Boston Study. The mean sVCAM-1 (±SD) concentration was 1192 ± 428 ng/mL. Over 5-years of follow-up, 10.2% of participants died. The baseline sVCAM-1 (±SD) concentration was 1434 ± 511 ng/mL in those who died vs. 1162 ± 402 ng/mL in those who survived (P < 0.0001). sVCAM-1 level was associated with recurrent falls (P < 0.01); compared to the lowest quintile, the highest quintile of sVCAM-1 was associated with increased risk of injurious falls [multivariable adjusted Incidence Rate Ratio = 1.9, 95% CI (1.2-2.9), P = 0.009]. On survival analysis, the highest sVCAM-1 quintile was associated with the greatest mortality over 5 years (log-rank test, P < 0.0001). The adjusted hazard ratio was 2.4 [95% CI (2.1-2.7), P = 0.002]. High sVCAM-1 blood concentration was strongly associated with recurrent falls, injurious falls, and mortality in older adults.

Indexed as

MortalityAccidental FallsAgedAged, 80 and overBiomarkersBostonFemaleHumansIndependent LivingMaleProspective StudiesSolubilitySurvival AnalysisTime FactorsVascular Cell Adhesion Molecule-1BiomarkersVascular Cell Adhesion Molecule-1Adhesion moleculeElderlyEndothelial dysfunctionInjurious fallsMortality

Identifiers

PMID29481968
PMCPMC6778959
OpenAlexW2793908636

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.